CNDP1 (CTG)5 allele and cardiovascular events in high-risk patients: LURIC study results

Abstract

Abstract Homozygous carriers of the CNDP1 (CTG) 5 allele with diabetes mellitus are believed to have a lower risk of developing diabetic kidney disease compared to individuals carrying alleles with higher numbers of this CTG repeat. However, recent studies claimed that homozygosity for the (CTG) 5 allele increases the risk of disease progression towards end-stage renal disease and even cardiovascular mortality, at least in women. Therefore, this study sought to confirm in a prospective manner in a cardiovascular high-risk cohort if individuals with two (CTG) 5 alleles indeed have an increased cardiovascular mortality. 3,201 individuals from the LURIC study were included and followed for a median of 9.9 years. CNDP1 (CTG) n genotypes were assessed and related to all-cause and cardiovascular mortality. 1,157 (36.1%) patients carried the homozygous CNDP1 (CTG) 5 genotype. No significant difference for all-cause and cardiovascular mortality was detected after multiple adjustments for cardiovascular risk factors, neither for the whole cohort nor for men or women, respectively. In this prospective cardiovascular high-risk cohort, homozygosity for the CNDP1 (CTG) 5 allele was not associated with increased cardiovascular mortality compared to all other genotypes together. These findings do not confirm previous reports suggesting a sex-specific increase in cardiovascular mortality among women carrying two (CTG) 5 alleles.